RTP Mobile Logo
Current and Future Treatment Algorithms in the Management of Metastatic Castration-Resistant Prostate Cancer
Released July 2014

Featuring perspectives from Dr David I Quinn. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for medical and radiation oncologists, urologists and other healthcare providers involved in the treatment of prostate cancer (PC).

    OVERVIEW OF ACTIVITY
    Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year, accounting for almost 30% of all newly diagnosed human cancers. Tumors of the prostate are the most prevalent and are therefore the focus of extensive ongoing clinical research.

    Although virtually all locally advanced or metastatic sites of tumor are initially reliant upon androgen stimulation for growth and respond to treatment with androgen deprivation therapy, inevitably resistance to hormone blockade eventually develops, culminating in the recurrence of highly aggressive castration-resistant PC (CRPC). Research advances focused specifically on this population occurring within the past several years have resulted in a paradigm shift to the multidisciplinary care of this disease. Because of this, a once stagnant systemic treatment algorithm largely confined to medical or surgical castration has evolved into delivery of cutting-edge antineoplastic therapy. To bridge the gap between research and patient care, this program uses a video presentation by Dr David Quinn to provide clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.

    LEARNING OBJECTIVES

    • Recall existing and emerging research information demonstrating the impact of secondary hormonal interventions on outcomes for patients with chemotherapy-naïve or pretreated CRPC, and use this information to guide treatment planning for these patients.
    • Identify and educate patients with skeletal metastases about the efficacy and safety of radium-223.
    • Recognize the unique patterns of response with available and emerging immunotherapeutic strategies, and effectively counsel patients considering these treatments.
    • Apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. The participant should watch the video.


    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Presenting Faculty Member

    David I Quinn, MBBS, PhD
    Medical Director, Norris Cancer Hospital and Clinics
    Leader, Developmental Therapeutics
    Head, GU Cancer Section
    Division of Cancer Medicine and Blood Diseases
    USC/Norris Comprehensive Cancer Center
    Los Angeles, California

    Advisory Committee: Amgen Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Pfizer Inc, Prometheus Laboratories Inc, Teva Oncology, Veridex LLC; Paid Research: Millennium: The Takeda Oncology Company, Sanofi; Other Remunerated Activities: Medivation Inc, Teva Oncology.

    Project Steering Committee Members

    Andrew J Armstrong, MD, ScM
    Associate Professor of Medicine and Surgery
    Duke Cancer Institute
    Duke University
    Durham, North Carolina

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Consulting Agreements: Active Biotech AB, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Ipsen, Sanofi; Contracted Research: Active Biotech AB, Astellas, Bristol-Myers Squibb Company, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Ipsen, Janssen Pharmaceuticals Inc, KangLaiTe USA, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Speakers Bureau: Amgen Inc, Dendreon Corporation, Pfizer Inc, Sanofi.

    Tomasz M Beer, MD
    Grover C Bagby Endowed Chair for Prostate Cancer Research
    Professor of Medicine, Hematology and Medical Oncology
    Deputy Director, OHSU Knight Cancer Institute
    Portland, Oregon

    Consulting Agreement: Dendreon Corporation; Contracted Research: Astellas, Bristol-Myers Squibb Company, Cougar Biotechnology Inc, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Janssen Biotech Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc.

    Robert Dreicer, MD, MS
    Chairman, Department of Solid Tumor Oncology
    Taussig Cancer Institute
    Cleveland Clinic
    Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Cleveland, Ohio

    Advisory Committee: AbbVie Inc, Dendreon Corporation, Endo Pharmaceuticals, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Mount Sinai School of Medicine
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    New York, New York

    Advisory Committee: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc.

    Daniel P Petrylak, MD
    Professor of Medicine
    Program Director, Genitourinary Oncology
    Co-Director, Signal Transduction Program
    Yale Comprehensive Cancer Center
    New Haven, Connecticut

    Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Bellicum Pharmaceuticals Inc, Celgene Corporation, Pfizer Inc; Contracted Research: Celgene Corporation, Eisai Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly, Millennium: The Takeda Oncology Company, Sanofi; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc.

    A Oliver Sartor, MD
    Medical Director, Tulane Cancer Center
    Laborde Professor of Cancer Research
    Professor of Medicine and Urology
    Tulane Medical School
    New Orleans, Louisiana

    Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bayer HealthCare Pharmaceuticals, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Sanofi.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation and Millennium: The Takeda Oncology Company.

    Hardware/Software Requirements:
    A high-speed Internet connection  
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2014
    Expiration date: July 2015

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Chapters:
00:00:01 - Introduction
00:01:49 - Recent FDA approvals and the impact on nonprotocol care 
00:15:42 - Bone-targeted therapy — Radium-223 
00:31:06 - Novel endocrine agents — Abiraterone, enzalutamide, orteronel 
00:57:57 - Immune-based treatment — Sipuleucel-T  
01:07:09 - New agents and strategies